Extended Data Fig. 8: Evaluation of the impact of vaccine boosting of CAR-T cells on LN architecture and induction of serum antibodies against amph-mimotope vaccine.
(a) Experimental setup and timeline. C57BL/6 mice were lymphodepleted (L.D.) and injected with 0.5x106 hCD19+ Eμ-Myc cells. On day 7, mice were adoptively transferred with 2×106 FMC63-mCAR-T cells or control T cells, then vaccinated 1 day later with 10 μg amph-F12-A1 (Vax). Inguinal (draining) lymph nodes were collected on day 15, frozen, and stained for CD3, B220, and CD11c. (b) Confocal imaging of LNs. Shown are LN sections stained with anti-CD3, anti-B220, and anti-CD11c to define the T cell zone, B cell zone and DC populations in the LN. (c) Evaluation of serum antibody against amph-mimotope vaccine. Serum was collected from FMC63-mCAR-T- and FMC63-mCAR-T + Vax-treated Eμ-Myc-bearing mice on day 21 (timeline presented in Fig. 6a) for analysis of mimotope-specific IgG by ELISA (n = 7 for FMC63-mCAR-T, n = 8 for FMC63-mCAR-T + Vax). FMC63 IgG was used as a positive control. This data is related to Fig. 6. Error bars show mean±95% CI. ****, p < 0.0001; ns, non-significant by one-way ANOVA with Tukey’s post-test.
